ANDA 205685, held by Xellia Pharms Aps. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 205685 (Tobramycin Sulfate), held by Xellia Pharms Aps, was first approved by FDA on Sep 16, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tobramycin SulfateEQ 1.2GM BASE/VIAL · injectable;injection | Tobramycin Sulfate | Rx |
| May 30, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 10, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 16, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters